Document is current

Article History

Received: 23 January 2025

Accepted: 14 July 2025

First Online: 29 August 2025

Declarations

:

: The study protocol was approved by the Ethics Committee “Comité de Protection des Personnes (CPP)” Ile-de-France VI (CPP Ile-de-France VI, No. 34–17) on 9 June 2017 under the number 2017-A00731-52, and registered with ClinicalTrials.gov under the number NCT03351816. All patients provided written informed consent for participation. This study was performed in accordance with the Declaration of Helsinki.

: Not applicable.

: MB reports personal fees from Microport, Medtronic, Biosense Webster outside the submitted work; CdC reports personal fees from Biosense Webster, Medtronic, Stereotaxis, Mylan and nonfinancial support from Abbott and Microport outside the submitted work. JMS reports personal fees from Microport, Bayer, Mylan, Pfizer, and Boeringher outside the submitted work. NM reports personal fees from Abbott, Bayer, Boston Scientific, Bristol Myers Squibb, Edwards Lifesciences, and Terumo outside the submitted work. MFS reports personal fees from Astra Zeneca, Boehringer Ingelheim, Bayer, Bristol Myers Squibb, Novartis, and Servier outside the submitted work. FS reports grants and personal fees from Bayer, Sanofi Aventis, MSD, and Amgen; grants from St Jude Medical and Daiichi Sankyo; and personal fees from Boehringer Ingelheim, Pfizer, Astra Zeneca, Mylan, and Servier outside the submitted work. The remaining authors have no disclosures to report.